Medicure Inc. (OTCMKTS:MCUJF) Short Interest Down 66.7% in August
Medicure Inc. (OTCMKTS:MCUJF) Short Interest Down 66.7% in August
Medicure Inc. (OTCMKTS:MCUJF – Get Rating) was the target of a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 100 shares, a decline of 66.7% from the July 31st total of 300 shares. Based on an average trading volume of 16,600 shares, the days-to-cover ratio is presently 0.0 days.
Medicure Inc.（OTCMKTS: MCUJF — 獲取評級）是8月份空頭利率大幅下降的目標。截至8月15日，空頭利息總額爲100股，較7月31日的300股總額下降了66.7％。根據16,600股的平均交易量，目前的回報天數爲0.0天。
Medicure Trading Down 6.2 %
Medicure交易下跌6.2％
Shares of MCUJF stock opened at $0.79 on Friday. The company's fifty day simple moving average is $0.84 and its two-hundred day simple moving average is $0.84. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.61 and a quick ratio of 1.18. Medicure has a 1 year low of $0.64 and a 1 year high of $1.10. The stock has a market capitalization of $8.10 million, a price-to-earnings ratio of 14.04 and a beta of 0.83.
週五，MCUJF股票開盤價爲0.79美元。該公司的五十天簡單移動平均線爲0.84美元，其兩百天簡單移動平均線爲0.84美元。該公司的債務與權益比率爲0.04，流動比率爲1.61，速動比率爲1.18。Medicure的1年低點爲0.64美元，爲1年來的最高水平，爲1.10美元。該股票的市值爲810萬美元，市盈率爲14.04，beta值爲0.83。
Medicure (OTCMKTS:MCUJF – Get Rating) last issued its earnings results on Monday, May 30th. The company reported $0.04 earnings per share (EPS) for the quarter. Medicure had a net margin of 3.40% and a return on equity of 4.28%. The business had revenue of $4.51 million for the quarter.
Medicure（OTCMKTS: MCUJF — 獲取評級）最後一次發佈財報是在5月30日星期一。該公司報告本季度每股收益（EPS）爲0.04美元。Medicure的淨利潤率爲3.40％，股本回報率爲4.28％。該業務本季度的收入爲451萬美元。
About Medicure
關於 Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
Medicure Inc是一家生物製藥公司，從事加拿大和美國心血管市場人體療法的研究、開發和商業化。該公司銷售和分銷 EGRANSTAT 注射劑，這是一種糖蛋白 GP iib/IIIa 受體拮抗劑，用於治療急性冠脈綜合徵，包括不穩定型心絞痛和非 Q 波心肌梗死。
Featured Articles
精選文章
- Get a free copy of the StockNews.com research report on Medicure (MCUJF)
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?
- 免費獲取 StockNews.com 關於 Medicure 的研究報告 (MCUJF) 的副本
- AbbVie Inc. 應該在你的股息投資組合中佔有一席之地嗎？
- 盈利後價格上漲後，PayPal是買入嗎？
- 威廉姆斯-索諾瑪的高端消費者仍在消費
- Snowflake 股票因業績強勁而飆升
- ShockWave 在財報公佈後價格變動了 40%，令人震驚：這是買入嗎？
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Medicure Daily 的新聞和收視率 -在下面輸入您的電子郵件地址，以通過Marketbeat.com的免費每日電子郵件時事通訊接收Medicure及相關公司最新新聞和分析師評級的簡明每日摘要。